Key facts
- This page summarizes Isaac Barchas's Form 4 filing for Immunome Inc. (IMNM).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 02 Jul 2026, 20:31.
Isaac Barchas - 30 Jun 2026 Form 4 Insider Report for Immunome Inc. (IMNM)
- Reporting relationship
- Director
- Issuer ticker
- IMNM
- Reported as of
- 30 Jun 2026
- Net transaction value
- -$4,393,024
- SEC form
- 4
- Accepted by SEC
- 02 Jul 2026, 20:31:58 UTC
- Prior SEC filing
- 12 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sandra Stoneman, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Isaac Barchas filed Form 4 for Immunome Inc. (IMNM) on 02 Jul 2026.
Change
- Previous filing in this sequence was filed on 12 Jun 2026.
- Current net transaction value: -$4,393,024.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001808343
Primary reporting owner
Barchas Isaac
- Relationship
- Director
- Address
- C/O IMMUNOME, INC., 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL
- Signature
- /s/ Sandra Stoneman, Attorney-in-Fact
- Signature date
- 02 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMNM
transaction
Common Stock
Sale
- Transaction value
- $2,134,176
- Shares
- -101,050
- Change %
- -25%
- Price
- $21.12
- Shares after
- 308,504
- Date
- 30 Jun 2026
- Ownership
- See footnotes
- Footnotes
- F1, F2, F3, F4, F5
IMNM
transaction
Common Stock
Sale
- Transaction value
- $1,691,113
- Shares
- -75,665
- Change %
- -25%
- Price
- $22.35
- Shares after
- 232,839
- Date
- 02 Jul 2026
- Ownership
- See footnote
- Footnotes
- F1, F6, F7
IMNM
transaction
Common Stock
Sale
- Transaction value
- $567,736
- Shares
- -24,335
- Change %
- -10%
- Price
- $23.33
- Shares after
- 208,504
- Date
- 02 Jul 2026
- Ownership
- See footnote
- Footnotes
- F1, F7, F8
IMNM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 103,259
- Date
- 30 Jun 2026
- Ownership
- Direct
- Footnotes
- F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 9 footnotes
Footnote F1
The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC ("ABHMC") and Arsenal Bridge Venture II-B LLC ("ABV II-B"), each on March 31, 2026.
Footnote F2
The shares were sold as follows: 100,000 shares were sold by ABHMC and 1,050 shares were sold ABV II-B.
Footnote F3
The weighted average sale price for the transaction report was $21.12, and the range of prices were between $20.83 and $21.47, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Footnote F4
The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration, effected by each of Arsenal Bridge Venture II LLC ("ABV II") and ABV II-B to their respective members, including ABHMC, the managing member of ABV II and ABV II-B. The receipt of such shares by the Reporting Person constituted a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16, including Rule 16a-13. Following this transaction, ABHMC owns the remaining 308,504 shares of Issuer common stock.
Footnote F5
The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC and is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABV II-B. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Footnote F6
The weighted average sale price for the transaction report was $22.35, and the range of prices were between $22.015 and $23.015, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Footnote F7
ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Footnote F8
The weighted average sale price for the transaction report was $23.33, and the range of prices were between $23.03 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Footnote F9
The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration, effected by ABV II to its members of the shares received in such distributions by members, including the Reporting Person. The receipt of such shares by the Reporting Person constituted a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16, including Rule 16a-13.